Valneva shares reclaim their €2.68 resistance level and rise 1.5%
The Lyon-based vaccine maker extends its midday rebound in a Paris market trending higher. A technical level monitored for several weeks has just given way, a few days after new data was published on its chikungunya vaccine.
A €2.68 level broken intraday and now acting as support
Valneva shares gain 1.27% to €2.71 intraday, after breaking above their €2.68 resistance, a former ceiling that now acts as support. The stock holds above this level, with a last price at €2.72.
The gap is widening with the short-term moving averages: the price is 8.01% above the MM20 and 2.69% above the MM50, while the MM200 at €2.86 remains 5.21% above the price. This rebound is part of a positive streak, with +7.07% over the week, and places the stock among the gainers of the SBF 120, against the grain of its 29.44% decline over one year. It follows the seroresponse maintained at 94% five years after a single dose of Ixchiq, data published on November 10.
Sanofi, another stock in the sector, rises 1.66% the same day and is up 22.97% over one month.
2026 guidance confirmed and an investor meeting on November 16
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
When publishing its H1 2026 results on August 13, Valneva confirmed its outlook for the fiscal year, despite the persistent impact of the geopolitical context on travel.
The company also cited among its levers the regulatory decisions expected within twelve months on its Lyme disease vaccine candidate, developed with Pfizer, and an improvement in gross margins in the second half.
The laboratory is participating in the Jefferies Global Healthcare Conference on November 16. The RSI at 59 signals neither overbought conditions nor loss of momentum. The next technical level is resistance at €3.07.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
EBITDA margin: -60,4 %
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
